Skip to main content
. 2022 Nov 4;8:444. doi: 10.1038/s41420-022-01238-4

Fig. 4. GPR35 promotes cancer development and immune cells decreased in GC tumors.

Fig. 4

A Tissues and blood specificity of GPR35 in human. NX represents normalized expression. The consensus RNA data is based on normalized expression (NX) data from three different sources: Human Protein Atlas (HPA), GTEx and FANTOM5 project. B GPR35 expression landscape in cancers and corresponding normal tissues. C GPR35 expression level in different gender and stages for GC. The landscape of TMB (D) and purity (E) for GPR35 in cancers. F HR (hazard ratio) values for GPR35 in different clinical groups. G HR values for GPR35 in enriched or decreased immune cells. P values were calculated with the log-rank test.